NASDAQ
DRRX

Durect Corporation

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Durect Corporation Stock Price

Vitals

Today's Low:
$2.88
Today's High:
$3.031
Open Price:
$3
52W Low:
$3.165
52W High:
$9.7
Prev. Close:
$2.98
Volume:
127478

Company Statistics

Market Cap.:
$141.31 million
Book Value:
0.627
Revenue TTM:
$19.42 million
Operating Margin TTM:
-184.01%
Gross Profit TTM:
$16.48 million
Profit Margin:
-187.82%
Return on Assets TTM:
-32.17%
Return on Equity TTM:
-115.9%

Company Profile

Durect Corporation had its IPO on 2000-09-28 under the ticker symbol DRRX.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Durect Corporation has a staff strength of 75 employees.

Stock update

Shares of Durect Corporation opened at $3 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.88 - $3.03, and closed at $2.93.

This is a -1.68% slip from the previous day's closing price.

A total volume of 127,478 shares were traded at the close of the day’s session.

In the last one week, shares of Durect Corporation have slipped by -4.25%.

Durect Corporation's Key Ratios

Durect Corporation has a market cap of $141.31 million, indicating a price to book ratio of 2.3797 and a price to sales ratio of 3.9568.

In the last 12-months Durect Corporation’s revenue was $19.42 million with a gross profit of $16.48 million and an EBITDA of $-35609000. The EBITDA ratio measures Durect Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Durect Corporation’s operating margin was -184.01% while its return on assets stood at -32.17% with a return of equity of -115.9%.

In Q1, Durect Corporation’s quarterly earnings growth was a positive 0% while revenue growth was a positive 7.3%.

Durect Corporation’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.46

Its diluted EPS in the last 12-months stands at $-1.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.46. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Durect Corporation’s profitability.

Durect Corporation stock is trading at a EV to sales ratio of 2.3466 and a EV to EBITDA ratio of -1.8645. Its price to sales ratio in the trailing 12-months stood at 3.9568.

Durect Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$58.35 million
Total Liabilities
$42.09 million
Operating Cash Flow
$-4924000.00
Capital Expenditure
$0
Dividend Payout Ratio
0%

Durect Corporation ended 2024 with $58.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $58.35 million while shareholder equity stood at $15.34 million.

Durect Corporation ended 2024 with $0 in deferred long-term liabilities, $42.09 million in other current liabilities, 23000.00 in common stock, $-573369000.00 in retained earnings and $6.17 million in goodwill. Its cash balance stood at $39.30 million and cash and short-term investments were $44.22 million. The company’s total short-term debt was $22,958,000 while long-term debt stood at $0.

Durect Corporation’s total current assets stands at $50.50 million while long-term investments were $0 and short-term investments were $4.92 million. Its net receivables were $1.40 million compared to accounts payable of $2.01 million and inventory worth $2.21 million.

In 2024, Durect Corporation's operating cash flow was $-4924000.00 while its capital expenditure stood at $0.

Comparatively, Durect Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.93
52-Week High
$9.7
52-Week Low
$3.165
Analyst Target Price
$36.25

Durect Corporation stock is currently trading at $2.93 per share. It touched a 52-week high of $9.7 and a 52-week low of $9.7. Analysts tracking the stock have a 12-month average target price of $36.25.

Its 50-day moving average was $3.59 and 200-day moving average was $4.66 The short ratio stood at 3.64 indicating a short percent outstanding of 0%.

Around 149.4% of the company’s stock are held by insiders while 3957.5% are held by institutions.

Frequently Asked Questions About Durect Corporation

The stock symbol (also called stock or share ticker) of Durect Corporation is DRRX

The IPO of Durect Corporation took place on 2000-09-28

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$13.05
-0.25
-1.88%
$50.5
-1.54
-2.96%
Vaibhav Global Ltd (VAIBHAVGBL)
$414.65
-24.95
-5.68%
$66.01
-1.01
-1.51%
$23.11
-0.29
-1.24%
$9329.95
-190.05
-2%
$40.06
-0.05
-0.12%
$57.45
0.85
+1.5%
$0.84
0.02
+2.44%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Address

10260 Bubb Road, Cupertino, CA, United States, 95014-4166